AXIOS November 29, 2025
New pricing deals and aggressive marketing are transforming expensive GLP-1 weight-loss drugs into mainstream treatments and creating the next mega-market for the pharmaceutical industry.
Why it matters: Americans have shown they’re willing to pay thousands of dollars out of pocket for the treatments — making them more popular than ever even as insurers try to pump the brakes by restricting coverage.
- There may be more deals on the way. Eli Lilly and Novo Nordisk have already reduced prices for the leading GLP-1s in their recent agreement with President Trump in exchange for expanded access to millions of people on Medicare.
- Medical researchers also continue to find promising new medical uses for GLP-1s, including treatment of addiction, COPD and...
Today's Sponsors
Today's Sponsor